Journal for ImmunoTherapy of Cancer (Nov 2023)
721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors
- Anne Goubier,
- Neeltje Steeghs,
- Carlos Gomez-Roca,
- Philippe Cassier,
- Elena Fernandez,
- Eelke Gort,
- Hilde De Winter,
- Vaia Stavropoulou,
- Nina Stojcheva,
- Paul Baverel,
- Jennifer Krieg,
- Kyriaki Ioannou,
- Ana Maria Florescu,
- Lea Hoenig,
- Bruno Baud-Berthier,
- Michael P Sanderson,
- Vladimir Kirkin,
- Philippe Legenne
Affiliations
- Anne Goubier
- 4Molecular Partners AG, Schlieren, Switzerland
- Neeltje Steeghs
- 2Netherlands Cancer Institute, Amsterdam, Netherlands
- Carlos Gomez-Roca
- 7Institut Universitaire du Cancer, Oncopole, Toulouse, France
- Philippe Cassier
- 8Centre Leon Berard, Lyon, France
- Elena Fernandez
- 4Molecular Partners AG, Schlieren, Switzerland
- Eelke Gort
- 3UMC Utrecht, Utrecht, Netherlands
- Hilde De Winter
- 4Molecular Partners AG, Schlieren, Switzerland
- Vaia Stavropoulou
- 4Molecular Partners AG, Schlieren, Switzerland
- Nina Stojcheva
- 4Molecular Partners AG, Schlieren, Switzerland
- Paul Baverel
- 4Molecular Partners AG, Schlieren, Switzerland
- Jennifer Krieg
- 4Molecular Partners AG, Schlieren, Switzerland
- Kyriaki Ioannou
- 4Molecular Partners AG, Schlieren, Switzerland
- Ana Maria Florescu
- 4Molecular Partners AG, Schlieren, Switzerland
- Lea Hoenig
- 4Molecular Partners AG, Schlieren, Switzerland
- Bruno Baud-Berthier
- 4Molecular Partners AG, Schlieren, Switzerland
- Michael P Sanderson
- 4Molecular Partners AG, Schlieren, Switzerland
- Vladimir Kirkin
- 4Molecular Partners AG, Schlieren, Switzerland
- Philippe Legenne
- 4Molecular Partners AG, Schlieren, Switzerland
- DOI
- https://doi.org/10.1136/jitc-2023-SITC2023.0721
- Journal volume & issue
-
Vol. 11,
no. Suppl 1
Abstract
No abstracts available.
